The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
Open accessAbstract
Background: There is no standard serum biomarker used for diagnosis or early detection of recurrence for renal cell carcinoma (RCC) patients. MicroRNAs (miRNAs) are abundant and highly stable in blood serum, and have been recently described as powerful circulating biomarkers in a wide range of solid cancers. Our aim was to identify miRNA signature that can distinguish the blood serum of RCC patients and matched healthy controls and validate identified miRNAs as potential biomarkers for RCC. Methods: In the screening phase of the study, blood serum of 15 RCC patients and 12 matched healthy controls were analyzed by use of the TaqMan Low-Density Arrays enabling parallel identification of expression levels of 667 miRNAs through qRT-PCR-based approach. In the validation phase, identified miRNAs were further evaluated on the independent group of 90 RCC patients and 35 matched healthy controls by use of individual qRT-PCR assays and statistically evaluated. Results: We identified 30 miRNAs differentially expressed between serum of RCC patients and healthy controls: 19 miRNAs were up-regulated and 11 miRNAs were down-regulated in RCC patients. MiR-378, miR-451 and miR-150 were further evaluated in the independent group of patients, and two of them were successfully validated: levels of miR-378 were increased (p = 0.0003, AUC = 0.71), miR-451 levels were decreased (p < 0.0001, AUC = 0.77) in serum of RCC patients. Combination of miR-378 and miR-451 enable identification of RCC serum with the sensitivity of 81%, specificity 83% and AUC = 0.86. Conclusions: Circulating miRNAs in serum are promising biomarkers in RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedCirculating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., Banham, A. H., Pezzella, F., Boultwood, J., Wainscoat, J. S., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07077.x · Cited by 1,735
Ng, E. K. O., Chong, W. W. S., Jin, H., Lam, E. K. Y., Shin, V. Y., Yu, J., Poon, T. C. W., Ng, S. S. M., & Sung, J. J. Y. (2009) · Gut · doi:10.1136/gut.2008.167817 · Cited by 1,151 · cited 1×
“0003 colorectal carcinoma [16,17], oral squamous cell carcinoma [18], laryngeal carcinoma [19] SUFU, TUSC2, TOB2, CYP2E1”
BackgroundPlasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
Huang, Z., Huang, D., Ni, S., Peng, Z., Sheng, W., & Du, X. (2010) · International Journal of Cancer · doi:10.1002/ijc.25007 · Cited by 964
Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., Chen, Y., Xu, L., Zen, K., Zhang, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9342 · Cited by 798
Resnick, K. E., Alder, H., Hagan, J. P., Richardson, D. L., Croce, C. M., & Cohn, D. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.036 · Cited by 647
Circulating microRNAs in plasma of patients with gastric cancers
Tsujiura, M., Ichikawa, D., Komatsu, S., Shiozaki, A., Takeshita, H., Kosuga, T., Konishi, H., Morimura, R., Deguchi, K., Fujiwara, H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605608 · Cited by 628
Circulating microRNAs: Association with disease and potential use as biomarkers
Reid, G., Kirschner, M. B., & van Zandwijk, N. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.11.004 · Cited by 467
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K., & Schwarzenbach, H. (2010) · Breast Cancer Research · doi:10.1186/bcr2766 · Cited by 430
A Pilot Study of Circulating miRNAs as Potential Biomarkers of Early Stage Breast Cancer
Zhao, H., Shen, J., Medico, L., Wang, D., Ambrosone, C. B., & Liu, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013735 · Cited by 398 · cited 1×
“Several dysregulated miRNAs identified in our study have been described to have altered expression levels in plasma or serum of various cancers recently: up-regulated mir425* [28,29], let-7a [30] or let-7f [31].”
BackgroundMicroRNAs in colorectal cancer: translation of molecular biology into clinical application
Slaby, O., Svoboda, M., Michalek, J., & Vyzula, R. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-102 · Cited by 356
Self-citationBandres, E., Bitarte, N., Arias, F., Agorreta, J., Fortes, P., Agirre, X., Zarate, R., Diaz-Gonzalez, J. A., Ramirez, N., Sola, J. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1818 · Cited by 346
Silva, J., García, V., Zaballos, Á., Provencio, M., Lombardía, L., Almonacid, L., García, J. M., Domínguez, G., Peña, C., Diaz, R., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00029610 · Cited by 280
[8] Bioconductor: An Open Source Framework for Bioinformatics and Computational Biology
Reimers, M., & Carey, V. J. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(06)11008-3 · Cited by 261
MicroRNA Expression Profiling of Oral Carcinoma Identifies New Markers of Tumor Progression
Scapoli, L., Palmieri, A., Muzio, L. L., Pezzetti, F., Rubini, C., Girardi, A., Farinella, F., Mazzotta, M., & Carinci, F. (2010) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201002300427 · Cited by 234
MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2
Wu, Q., Jin, H., Yang, Z., Luo, G., Lu, Y., Li, K., Ren, G., Su, T., Pan, Y., Feng, B., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.182 · Cited by 225
Chow, T.-F. F., Youssef, Y. M., Lianidou, E., Romaschin, A. D., Honey, R. J., Stewart, R., Pace, K. T., & Yousef, G. M. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.07.020 · Cited by 214
Ma, Y., Zhang, P., Wang, F., Zhang, H., Yang, J., Peng, J., Liu, W., & Qin, H. (2012) · Gut · doi:10.1136/gutjnl-2011-301122 · Cited by 182
Slabý, O., Jančovičová, J., Lakomý, R., Svoboda, M., Poprach, A., Fabián, P., Křen, L., Michálek, J., & Vyzula, R. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-90 · Cited by 125
Self-citationMicro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia
Flamant, S., Ritchie, W., Guilhot, J., Holst, J., Bonnet, M., Chomel, J., Guilhot, F., Turhan, A., & Rasko, J. (2010) · Haematologica · doi:10.3324/haematol.2009.020636 · Cited by 117
MicroRNA profiling differentiates colorectal cancer according to KRAS status
Mosakhani, N., Sarhadi, V. K., Borze, I., Karjalainen‐Lindsberg, M., Sundström, J. T. T., Ristamäki, R., Osterlund, P. J., & Knuutila, S. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20925 · Cited by 115
Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues
Yi, Z., Fu, Y., Zhao, S., Zhang, X., & Ma, C. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0726-x · Cited by 105
MicroRNAs and their target gene networks in renal cell carcinoma
Rédová, M., Svoboda, M., & Slabý, O. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.01.019 · Cited by 77
Self-citationGrinchuk, O. V., Jenjaroenpun, P., Orlov, Y. L., Zhou, J., & Kuznetsov, V. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp954 · Cited by 55
Cited by
Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.5 · Cited by 969
Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., Wang, D., See, W., Costello, B. A., Quevedo, F., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.035 · Cited by 681
MicroRNAs and complex diseases: from experimental results to computational models
Chen, X., Xie, D., Zhao, Q., & You, Z.-H. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbx130 · Cited by 638
Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts
Yang, F., Ning, Z., Ma, L., Liu, W., Shao, C., Shu, Y., & Shen, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0718-4 · Cited by 329
The emerging role of extracellular vesicles as biomarkers for urogenital cancers
Nawaz, M., Camussi, G., Valadi, H., Nazarenko, I., Ekström, K., Wang, X., Principe, S., Shah, N., Ashraf, N. M., Fatima, F., et al. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.301 · Cited by 294
Metadata
- Authors
- Redova, M., Poprach, A., Nekvindova, J., Iliev, R., Radova, L., Lakomy, R., Svoboda, M., Vyzula, R., & Slaby, O.
- Venue
- Journal of Translational Medicine
- Published
- 2012-03-22
- Volume
- 10
- Issue
- 1
- Pages
- 55-55
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2111306860
- Cited by
- 268
- References
- 27
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.